Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
SDI continues to reward loyal retail investor fans
In the context of the global pandemic SDI’s (SDI:AIM) full year to 30 April 2021 results were impressive. In line with May’s trading update, revenue growth of 43.2% to £35.1 million (19% pre-acquisitions) and fully adjusted pre-tax profit soaring 70% to £7.4 million effectively beat market expectations in real terms.
Yes, there were some significant one-off Covid-19 related boosts which helped offset weakened demand elsewhere, but as the world gradually returns to normality analyst anticipate a return to steady and reliable progress.
As a reminder, SDI is a collection of multiple subsidiaries that design and manufacture digital imaging, sensing and control equipment used in life sciences, healthcare, astronomy, manufacturing, precision optics and art conservation applications.
Acquisitions are a major part of the story so it is pleasing to see growth opportunities enhanced by its latest, Monmouth Scientific. Strong cash generation (it cleared its £4 million net debt last year) and balance sheet strength underpin this acquisition strategy, with one analyst highlighting the benefit from the company’s increasingly diverse catalogue products and end markets.
‘With a good order book and good trading in May and June, as laboratories re-open post-pandemic, we leave revenues unchanged implying strong growth of 20%,’ FinnCap analysts said of their full year April 2022 forecasts.
SHARES SAYS: Still a great buy for the long-term.